Locally advanced gastric cancer
Conditions
Interventions
Case series:Apatinib combined with XELOX
Sponsors
The First Hospital of Lanzhou University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Pathologically confirmed locally advanced gastric cancer (t3-4n0-2M0), with measurable indicators (helical CT scan of 10 or more mm, meeting the RECIST 1.1 standard); 2. Aged 18~75 years; 3. KPS >= 70, and ECOG PS 0-2; 4. The standard of blood routine examination should meet: (no blood transfusion and blood products within 14 days, no g-csf and other hematopoietic stimulating factors were used for correction): ANC >= 1.5 x 10^9/L; PLT >= 80 x 10^9/L; Hb >= 90 g/L; 5. Biochemical examination shall meet the following standards: BIL 60 ml/min (Cockcroft - Gault); 7. Fertile woman must have a negative pregnancy test within 28 days of enrollment in the study (unless the amenorrhea has been 24 months);or must perform a pregnancy test (serum or urine) 7 days before screened; 8. Signed the Informed Consent Form (Informed Consent Form should be subject to approval by the independent ethics committee and informed consent of the prior to the commencement of any substantive trial procedure).
Exclusion criteria
Exclusion criteria: 1. Well differentiated adenocarcinoma; 2. Have other malignant tumors in the past; 3. Remnant gastric cancer; 4. Have received chemotherapy or radiation before; 5. Distant metastasis; 6. AST and/or ALT > 2.5xULN, with ALP > 5xULN; 7. Any uncontrolled systemic disease, including active infection, uncontrolled hypertension, diabetes, unstable angina, congestive heart failure, myocardial infarction (within 1 year before treatment), severe arrhythmia requiring medication, liver diseases and kidney diseases and metabolic diseases; 8. Patients with central nervous system diseases or peripheral nervous system diseases or mental diseases; 9. A woman who is pregnant or lactating; 10. Undergo experimental treatment in other clinical studies (in the treatment phase of clinical studies); 11. Known to be allergic to potentially used chemotherapy drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| pathologic complete response;Objective Remission Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| the rate of R0;Disease Control Rate ;DFS;QoL;safety; | — |
Countries
China
Contacts
Public ContactGuan Quanlin
the first hospital of Lanzhou university
Outcome results
None listed